ENDOBRONCHIAL
BRACHYTHERAPY
Dr.Tinku Joseph
DM Resident
AIMS, Kochi
Lecture given at Hospital
Serdang, Malaysia
Contents
 Overview
 Technique
 Types
 Indications
 Complications
Endobronchial Brachytherapy (EBBT)
 Placement of a radioactive source within or in
close proximity to a malignancy in order to provide
high doses of radiation in close proximity to the
tumor.
 Palliative therapy
 Recently-: need for this technique has declined.
Goal-:
 Reduction in tumor size so that airway symptoms can
be relieved.
 Compared with (EBRT), EBBT - local radiation is
provided to the lesion (spares other tissues).
Technique
1. Selection of patients
2. Planning phase
3. FOB/Rigid with or without MV
support
4. Placement of Radioactive source
(Ir-192)
5. Fluroscopy
6. HDR/LDR given
Technique
Technique (step 1)
Technique (step 2)
Technique (step 3)
Technique (step 4)
1
2
Radiation Type
 Dose rate of brachytherapy depends upon the energy
and rate of decay of the radionuclide used.
 Commonly used-: Iridium192
• According to dose rate
1) High dose rate (HDR)-
- >12 Gy/Hr
2) Medium dose rate (MDR)
- 2-12 Gy/Hr
3)Low dose rate (LDR) -
- 0.4 -2 Gy/Hr
4)Ultra low dose rate (ULDR)-
-0.01-0.3 Gy/Hr
ISOTOPES USED IN BRACHYTHERAPY
can be embedded in
 Surface Applicator- placed directly on surface of tumor eg. Hard
palate, skin, ocular
 Intracavitory- inserted into specially designed apparatus that is
placed into body cavity eg. Gynec.malign, nasopharynx
 Intraluminal- Various organs with lumen
 (Oesophagus, endobronchial, biliary etc.)
 Interstitial- Directly through tissues encompassing tumor
 Intravascular- coronaries, peripheral art. internal mammary etc.
 10 to 12 Gray (Gy)/hour,
 Total dose - ranging from 5 to 40 Gy,
 Dose per session (fraction) varying from 3 to 10 Gy.
 Treated every 1-2 weeks (takes few mins)
HDR/LDR:
 Treatment times are shorter
 outpatient procedure.
 Increase procedure efficiency,
 Reduce treatment cost.
 Simpler and safer therapy.
Radiation Type- HDR
Radiation Type- LDR
 Delivers less than 2 Gy/hour
 Total dose of 1500 to 5000 Gy,
 Given over a few days (usually up to three days)
Disadvantages:
 Manual manipulation of the radionuclide
 30 to 70 hours of continuous treatment,
 Cumbersome radiation protection measures
 Catheter has to be left in place for the few days of
administration.
 Inpatient procedure
 Catheter displacement
 More costly than HDR EBBT
 Largely fallen out of favor.
Radiation Type- LDR
Indications
1. palliative treatment of large
obstructing central airway tumors
(NSCLC).
2. Metastatic airway tumors.
3. Early NSCLC that is limited to the
airway.
4. Benign tracheal stenosis
Palliation of central obstructing airway
tumors
 Palliation of obstructive symptoms caused by large
central airway tumors that are not amenable to
surgical resection and/orEBRT.
 Patients cannot tolerate or fail other local ablative
therapies (Nd:YAG laser, APC, or cryotherapy).
Types of cancer that are responsive to EBBT
 Biopsy proven NSCLC
 Early NSCLC localized to the airway.
 Positive resection margins or a stump
 Recurrence following surgery.
 Extrathoracic malignancy metastatic to lung
 Small cell carcinoma/carcinoid (no response)
Palliation of central obstructing airway
tumors
EBBT - patient or tumor criteria
Acute life threatening symptoms of airway obstruction
 First-: local ablative therapies or EBRT
 Followed by EBBT
• Efficacy:
 Subjective and objective improvement following
EBBT (20 to 100 % of patients).
 No survival benefit associated with EBBT or EBBT in
combination with chemotherapy.
 EBBT + Coventional methods (beneficial)
Palliation of central obstructing airway
tumors
 Hemoptysis improve most readily (90% response
rate)
 Cough and dyspnea may improve less reliably,
(underlying conditions such as COPD or radiation
fibrosis).
 Responses in tumor size and the degree of airway
obstruction are most commonly evaluated by chest
radiography and bronchoscopy.
 70 % of patients have greater than 50% improvement
in patency that persists for at least six months.
Palliation of central obstructing airway
tumors
Benign airway stenosis
Recurrent tracheal stenosis
 Following repeated attempts at dilation and stenting,
HDR EBBT (eg, a single 3 to 10Gray [Gy] dose of
Iridium192) is beneficial.
 Prevents formation of granulation tissue and reduce
the recurrence rate of restenosis.
 Role in post TB stenosis ???
Contraindications- Absolute
1) presence of fistulas between bronchi and
other structures.
 (EBBT increases the risk of viscus rupture and
fatal hemorrhage)
2) Presence of high grade airway obstruction.
 Try other modalities first
 use of brachytherapy will not immediately
shrink tumor size
 (maximal effect is after three weeks)
 may result in postradiation tissue edema and
complete airway obstruction.
 Moribund patients.
 Other absolute
contraindications to
bronchoscopy in general.
Contraindications- Absolute
1. Lesions in close proximity to large
vessels
2. Malignant involvement of the major
arteries
3. Significant destruction of the bronchial
wall
4. Mediastinal invasion
Contraindications- Relative
High risk of fistula formation and fatal hemorrhage
Complications
 <5%. Range (5-40%)
 Early (hours to days) or late (days
to weeks).
Early:
 Infrequent
 Usually due to bronchoscopy or
catheter insertion.
 Hemoptysis
 Catheter displacement
 Early complications of
bronchoscopy
Late:
 Radiation bronchitis
 Airway stenosis.
 Massive hemoptysis
 Fistula formation
Complications
Conclusions (EBBT)
 Placement of a radioactive source
within or in close proximity to a
malignancy in order to provide high
doses of radiation close to the tumor.
 EBBT is a good palliative treatment
for endoluminal neoplasms of the
lungs, either alone or in combination
with other procedures.
 Used in benign airway stenosis.
 HDR/LDR EBBT
 Bronchoscopy guided procedure.
 Combined with EBRT/APC/Nd YAG
(better results)
 Good tolerance and low
complication rate.
Conclusions
Endobronchial Brachytherapy by  Dr.Tinku Joseph
Endobronchial Brachytherapy by  Dr.Tinku Joseph

Endobronchial Brachytherapy by Dr.Tinku Joseph

  • 1.
    ENDOBRONCHIAL BRACHYTHERAPY Dr.Tinku Joseph DM Resident AIMS,Kochi Lecture given at Hospital Serdang, Malaysia
  • 2.
    Contents  Overview  Technique Types  Indications  Complications
  • 3.
    Endobronchial Brachytherapy (EBBT) Placement of a radioactive source within or in close proximity to a malignancy in order to provide high doses of radiation in close proximity to the tumor.  Palliative therapy  Recently-: need for this technique has declined.
  • 4.
    Goal-:  Reduction intumor size so that airway symptoms can be relieved.  Compared with (EBRT), EBBT - local radiation is provided to the lesion (spares other tissues). Technique
  • 5.
    1. Selection ofpatients 2. Planning phase 3. FOB/Rigid with or without MV support 4. Placement of Radioactive source (Ir-192) 5. Fluroscopy 6. HDR/LDR given Technique
  • 6.
  • 7.
  • 8.
  • 10.
  • 11.
  • 12.
    Radiation Type  Doserate of brachytherapy depends upon the energy and rate of decay of the radionuclide used.  Commonly used-: Iridium192 • According to dose rate 1) High dose rate (HDR)- - >12 Gy/Hr 2) Medium dose rate (MDR) - 2-12 Gy/Hr 3)Low dose rate (LDR) - - 0.4 -2 Gy/Hr 4)Ultra low dose rate (ULDR)- -0.01-0.3 Gy/Hr
  • 13.
    ISOTOPES USED INBRACHYTHERAPY can be embedded in  Surface Applicator- placed directly on surface of tumor eg. Hard palate, skin, ocular  Intracavitory- inserted into specially designed apparatus that is placed into body cavity eg. Gynec.malign, nasopharynx  Intraluminal- Various organs with lumen  (Oesophagus, endobronchial, biliary etc.)  Interstitial- Directly through tissues encompassing tumor  Intravascular- coronaries, peripheral art. internal mammary etc.
  • 14.
     10 to12 Gray (Gy)/hour,  Total dose - ranging from 5 to 40 Gy,  Dose per session (fraction) varying from 3 to 10 Gy.  Treated every 1-2 weeks (takes few mins) HDR/LDR:  Treatment times are shorter  outpatient procedure.  Increase procedure efficiency,  Reduce treatment cost.  Simpler and safer therapy. Radiation Type- HDR
  • 16.
    Radiation Type- LDR Delivers less than 2 Gy/hour  Total dose of 1500 to 5000 Gy,  Given over a few days (usually up to three days) Disadvantages:  Manual manipulation of the radionuclide  30 to 70 hours of continuous treatment,  Cumbersome radiation protection measures  Catheter has to be left in place for the few days of administration.
  • 17.
     Inpatient procedure Catheter displacement  More costly than HDR EBBT  Largely fallen out of favor. Radiation Type- LDR
  • 18.
    Indications 1. palliative treatmentof large obstructing central airway tumors (NSCLC). 2. Metastatic airway tumors. 3. Early NSCLC that is limited to the airway. 4. Benign tracheal stenosis
  • 19.
    Palliation of centralobstructing airway tumors  Palliation of obstructive symptoms caused by large central airway tumors that are not amenable to surgical resection and/orEBRT.  Patients cannot tolerate or fail other local ablative therapies (Nd:YAG laser, APC, or cryotherapy).
  • 20.
    Types of cancerthat are responsive to EBBT  Biopsy proven NSCLC  Early NSCLC localized to the airway.  Positive resection margins or a stump  Recurrence following surgery.  Extrathoracic malignancy metastatic to lung  Small cell carcinoma/carcinoid (no response) Palliation of central obstructing airway tumors
  • 21.
    EBBT - patientor tumor criteria
  • 23.
    Acute life threateningsymptoms of airway obstruction  First-: local ablative therapies or EBRT  Followed by EBBT • Efficacy:  Subjective and objective improvement following EBBT (20 to 100 % of patients).  No survival benefit associated with EBBT or EBBT in combination with chemotherapy.  EBBT + Coventional methods (beneficial) Palliation of central obstructing airway tumors
  • 24.
     Hemoptysis improvemost readily (90% response rate)  Cough and dyspnea may improve less reliably, (underlying conditions such as COPD or radiation fibrosis).  Responses in tumor size and the degree of airway obstruction are most commonly evaluated by chest radiography and bronchoscopy.  70 % of patients have greater than 50% improvement in patency that persists for at least six months. Palliation of central obstructing airway tumors
  • 25.
    Benign airway stenosis Recurrenttracheal stenosis  Following repeated attempts at dilation and stenting, HDR EBBT (eg, a single 3 to 10Gray [Gy] dose of Iridium192) is beneficial.  Prevents formation of granulation tissue and reduce the recurrence rate of restenosis.  Role in post TB stenosis ???
  • 28.
    Contraindications- Absolute 1) presenceof fistulas between bronchi and other structures.  (EBBT increases the risk of viscus rupture and fatal hemorrhage) 2) Presence of high grade airway obstruction.  Try other modalities first  use of brachytherapy will not immediately shrink tumor size  (maximal effect is after three weeks)  may result in postradiation tissue edema and complete airway obstruction.
  • 29.
     Moribund patients. Other absolute contraindications to bronchoscopy in general. Contraindications- Absolute
  • 30.
    1. Lesions inclose proximity to large vessels 2. Malignant involvement of the major arteries 3. Significant destruction of the bronchial wall 4. Mediastinal invasion Contraindications- Relative High risk of fistula formation and fatal hemorrhage
  • 31.
    Complications  <5%. Range(5-40%)  Early (hours to days) or late (days to weeks). Early:  Infrequent  Usually due to bronchoscopy or catheter insertion.  Hemoptysis  Catheter displacement  Early complications of bronchoscopy
  • 32.
    Late:  Radiation bronchitis Airway stenosis.  Massive hemoptysis  Fistula formation Complications
  • 33.
    Conclusions (EBBT)  Placementof a radioactive source within or in close proximity to a malignancy in order to provide high doses of radiation close to the tumor.  EBBT is a good palliative treatment for endoluminal neoplasms of the lungs, either alone or in combination with other procedures.
  • 34.
     Used inbenign airway stenosis.  HDR/LDR EBBT  Bronchoscopy guided procedure.  Combined with EBRT/APC/Nd YAG (better results)  Good tolerance and low complication rate. Conclusions